No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 343 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR Brothers Start Nonprofit To Help Fellow Teens Struggling With Mental Health... December 30, 2021 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective January 30, 2024 Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO... April 18, 2022 Adding Olanzapine to Standard Triple Antiemetic Therapy for the Prevention of... July 23, 2024 Load more HOT NEWS For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with...
